CN112334458A - 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 - Google Patents

3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 Download PDF

Info

Publication number
CN112334458A
CN112334458A CN201980035221.3A CN201980035221A CN112334458A CN 112334458 A CN112334458 A CN 112334458A CN 201980035221 A CN201980035221 A CN 201980035221A CN 112334458 A CN112334458 A CN 112334458A
Authority
CN
China
Prior art keywords
cancer
compound
independently selected
alkyl
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980035221.3A
Other languages
English (en)
Other versions
CN112334458B (zh
Inventor
陈向阳
庞育成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of CN112334458A publication Critical patent/CN112334458A/zh
Application granted granted Critical
Publication of CN112334458B publication Critical patent/CN112334458B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及一种新的调控或抑制吲哚胺2,3‑双加氧酶（IDO）活性的3‑吲唑啉酮类化合物，其制备方法及其在医药学上的应用。具体而言，本发明涉及一种通式（I）所示的化合物及其可药用的盐、含有所述化合物或其可药用的盐的药物组合物、应用所述化合物或其可药用的盐治疗和/或预防IDO介导的相关性病症、特别是肿瘤的方法以及所述化合物或其可药用的盐的制备方法。本发明还涉及所述化合物或其可药用的盐或含有所述化合物或其可药用的盐的药物组合物在制备用于治疗和/或预防IDO介导的相关性病症、特别是肿瘤的药物中的用途。其中通式（I）的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201980035221.3A 2018-05-25 2019-05-09 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 Active CN112334458B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018105002904 2018-05-25
CN201810500290.4A CN110526898A (zh) 2018-05-25 2018-05-25 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
PCT/CN2019/086258 WO2019223548A1 (zh) 2018-05-25 2019-05-09 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用

Publications (2)

Publication Number Publication Date
CN112334458A true CN112334458A (zh) 2021-02-05
CN112334458B CN112334458B (zh) 2022-11-08

Family

ID=68616195

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810500290.4A Pending CN110526898A (zh) 2018-05-25 2018-05-25 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
CN201980035221.3A Active CN112334458B (zh) 2018-05-25 2019-05-09 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810500290.4A Pending CN110526898A (zh) 2018-05-25 2018-05-25 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用

Country Status (5)

Country Link
US (1) US20210221808A1 (zh)
EP (1) EP3805212A4 (zh)
JP (1) JP2021525264A (zh)
CN (2) CN110526898A (zh)
WO (1) WO2019223548A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN114853672B (zh) * 2022-05-12 2023-06-23 中国人民解放军北部战区总医院 作为CDKs抑制剂的他克林衍生物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173496A (en) * 1987-01-19 1992-12-22 Ici Pharma Therapeutic preparations containing indazole derivatives
CN101282939A (zh) * 2005-10-12 2008-10-08 塞诺菲-安万特股份有限公司 作为脂肪酶和磷脂酶抑制剂的二酰基吲唑衍生物
WO2009127338A1 (de) * 2008-04-14 2009-10-22 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte carbonsäure-derivate und ihre verwendung
CN101932325A (zh) * 2007-11-30 2010-12-29 新联基因公司 Ido抑制剂
KR20120095133A (ko) * 2011-02-18 2012-08-28 사단법인 분자설계연구소 약물의 Ｃａｃｏ-2 세포 투과도 예측에 관한 정보제공방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013977A (es) 2005-05-10 2008-02-05 Incyte Corp Moduladores de 2,3-dioxigenasa indolamina y metodos de uso de los mismos.
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
US9067923B2 (en) 2011-11-09 2015-06-30 Kyowa Hakko Kirin Co., Ltd. Substituted quinoxalines
BR112015022575B1 (pt) 2013-03-14 2022-03-22 Curadev Pharma Private Ltd Composto, pró-drogas de um composto, composição e método para preparar um composto
WO2015002918A1 (en) 2013-07-01 2015-01-08 Bristol-Myers Squibb Company Ido inhibitors
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2016161960A1 (en) 2015-04-10 2016-10-13 Beigene, Ltd. NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
CA2929848A1 (en) 2015-05-14 2016-11-14 Pfizer Inc. Combination therapies comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-pd1/anti-pd-l1 antibody
KR20180095517A (ko) 2015-11-04 2018-08-27 인사이트 코포레이션 인돌아민 2,3-다이옥시게나제 저해를 위한 약제학적 조성물 및 방법 및 이에 대한 적응증
JP2019516682A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
WO2018039512A1 (en) * 2016-08-26 2018-03-01 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10882856B2 (en) * 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173496A (en) * 1987-01-19 1992-12-22 Ici Pharma Therapeutic preparations containing indazole derivatives
CN101282939A (zh) * 2005-10-12 2008-10-08 塞诺菲-安万特股份有限公司 作为脂肪酶和磷脂酶抑制剂的二酰基吲唑衍生物
CN101932325A (zh) * 2007-11-30 2010-12-29 新联基因公司 Ido抑制剂
WO2009127338A1 (de) * 2008-04-14 2009-10-22 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte carbonsäure-derivate und ihre verwendung
KR20120095133A (ko) * 2011-02-18 2012-08-28 사단법인 분자설계연구소 약물의 Ｃａｃｏ-2 세포 투과도 예측에 관한 정보제공방법

Also Published As

Publication number Publication date
WO2019223548A1 (zh) 2019-11-28
US20210221808A1 (en) 2021-07-22
CN110526898A (zh) 2019-12-03
EP3805212A1 (en) 2021-04-14
CN112334458B (zh) 2022-11-08
EP3805212A4 (en) 2022-03-02
JP2021525264A (ja) 2021-09-24

Similar Documents

Publication Publication Date Title
CN112300194B (zh) 一类稠环吡啶酮类化合物、制备方法和用途
KR20210121168A (ko) 복소환식 화합물인 벤조피리돈 및 그 사용
CN109689652B (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
CN110325514B (zh) 作为二氢乳清酸加氧酶抑制剂的1,4,6-三取代的-2-烷基-1H-苯并[d]咪唑衍生物
WO2021180072A1 (en) Heterocyclic compounds for inhibiting tyk2 activities
CN114163457A (zh) 嘧啶并五元氮杂环化合物及其用途
CN114075190A (zh) 杂环类btk抑制剂
CN112334458A (zh) 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
WO2020224626A9 (zh) 用作激酶抑制剂的化合物及其应用
WO2019228170A1 (zh) 八氢戊搭烯类化合物、其制备方法及其在医药学上的应用
CN115197221B (zh) 二氢吡唑并嘧啶酮类大环衍生物及其用途
JP6854497B2 (ja) インドールアミン−２，３−ジオキシゲナーゼ阻害剤としてのスルホニルアミディーン及びその製造方法と用途
CN110092750B (zh) 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用
JP7329052B2 (ja) フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用
CN112876456A (zh) 噌啉化合物pi3k激酶抑制剂及其制备方法与在制药中的应用
CN115776983A (zh) 杂环类免疫调节剂
CN112384506B (zh) 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN112209933B (zh) 含有4-氮杂螺庚烷的btk抑制剂
CN108047231B (zh) [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用
EP4317143A1 (en) Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof
CN115141176A (zh) 炔代吲哚类fgfr抑制剂及其制备方法和用途
CN118005656A (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
WO2019141095A1 (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
EA045833B1 (ru) Соединение, используемое как ингибитор киназы, и его применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045713

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant